Q-omics provides the consensus-scored IRAK3 profile across patient tissues and cancer cell-line models. IRAK3 expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in HNSC. Among the 18 cancer types available for tumor–normal comparison, IRAK3 is differentially expressed in 14, with the highest sampling consensus in KICH. Additionally, IRAK3 protein abundance shows 31,218 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight HNSC, KICH, and LSCC as cancer lineages where IRAK3 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for IRAK3 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes IRAK3 survival associations across molecular data types. IRAK3 RNA expression shows survival associations in the most cancer types (22), followed by mutation status (9) and mass-spec protein abundance (12). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible IRAK3 RNA expression–survival associations across cancer types. High IRAK3 expression shows unfavorable associations in LGG and ESCA, but favorable associations in HNSC, KIRC, CHOL and ACC. The HNSC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify HNSC as the clearest survival context for IRAK3 RNA expression.
This table summarizes IRAK3 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14, while mass-spec protein shows differences in 9. The strongest signals are observed in KICH for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for IRAK3. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. IRAK3 shows lower tumor expression in KICH, LUSC, LUAD, BLCA and THCA and higher tumor expression in KIRC. The KICH box plot shows higher IRAK3 RNA expression in normal versus tumor tissue (log2 FC = −1.241, t-test p < 0.001).
This table shows molecular features associated with IRAK3 in patient tissues and cancer cell lines. In patient samples, IRAK3 shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, IRAK3 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_SCLC, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Leukemia and LARGE_INTESTINE.
